Skip to main content

Advertisement

SpringerLink
Log in

Rechallenge of Trastuzumab-based Therapy in HER2-Positive Breast Cancer Patients who Progressed Under TDM-1

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Data on rechallenges of HER2 targetted agents in breast cancer patients is limited. The goal of the study was to evaluate the effectiveness of trastuzumab-based therapy in patients who progressed under trastuzumab emtansine (TDM-1). The study was designed as a retrospective observational study. Survival plots were performed with the Kaplan–Meier method. Fifteen patients were involved in the study. The average age was 45 (range, 30–66). De novo metastatic patient number was six (40%), and the average number of metastatic sites was 2 (range, 1–4) at diagnosis. Fourteen patients (92.3%) had undergone breast surgery (lumpectomy or mastectomy). All patients previously had been treated with trastuzumab-based chemotherapy and TDM-1. Also, nine (60%) patients had received endocrine therapy, and nine (60%) patients had palliative radiotherapy. After progression under TDM-1, patients received trastuzumab with chemotherapy (73.3%) or alone (26.7%). The overall response ratio was 66.7%. Median progression-free survival was 9.4 months (95% CI, 3.4–15.3). The median OS duration was 24.2 (95% CI, 13.5–34.9) months. Toxicity in all grades was observed in ten (66.7%) patients, and grade 3–4 toxicity (anemia and neutropenia) in two patients (13.3%). This study showed that rechallenge trastuzumab-based therapy was effective and good-tolerated in heavily pretreated patients who had progressed under TDM-1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

This published paper contains all of the data produced or analyzed during this investigation. Further enquiries can be directed to the corresponding author.

References

  1. Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763

    Article  PubMed  Google Scholar 

  2. Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–717. https://doi.org/10.1016/S0140-6736(05)66544-0

    Article  CAS  Google Scholar 

  3. Szymiczek A, Lone A, Akbari MR (2021) Molecular intrinsic versus clinical subtyping in breast cancer: a comprehensive review. Clin Genet 99:613–37. https://doi.org/10.1111/cge.13900

    Article  CAS  PubMed  Google Scholar 

  4. Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A (2021) Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel) 13. https://doi.org/10.3390/cancers13174287

  5. Raghav KPS, Moasser MM (2022) Molecular pathways and mechanisms of HER2 in cancer therapy. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-22-0283

  6. Sapino A, Goia M, Recupero D, Marchio C (2013) Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial ıssues. Front Oncol 3:129. https://doi.org/10.3389/fonc.2013.00129

    Article  PubMed  PubMed Central  Google Scholar 

  7. Oh DY, Bang YJ (2020) HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol 17:33–48. https://doi.org/10.1038/s41571-019-0268-3

    Article  CAS  PubMed  Google Scholar 

  8. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V et al (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21:519–30. https://doi.org/10.1016/S1470-2045(19)30863-0

    Article  CAS  PubMed  Google Scholar 

  9. Krop IE, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, Smitt M et al (2014) Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15:689–99. https://doi.org/10.1016/S1470-2045(14)70178-0

    Article  CAS  PubMed  Google Scholar 

  10. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382:610–21. https://doi.org/10.1056/NEJMoa1914510

    Article  CAS  PubMed  Google Scholar 

  11. Hanovich E, Asmis T, Ong M, Stewart D (2020) Rechallenge strategy in cancer therapy. Oncology 98:669–79. https://doi.org/10.1159/000507816

    Article  CAS  PubMed  Google Scholar 

  12. Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G et al (2012) Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol 23:1436–41. https://doi.org/10.1093/annonc/mdr474

    Article  CAS  PubMed  Google Scholar 

  13. Araki K, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T et al (2015) Trastuzumab rechallenge after lapatinib- and trastuzumab-resistant disease progression in HER2-positive breast cancer. Clin Breast Cancer 15:432–9. https://doi.org/10.1016/j.clbc.2015.06.002

    Article  CAS  PubMed  Google Scholar 

  14. Andre F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G et al (2023) Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401:1773–85. https://doi.org/10.1016/S0140-6736(23)00725-0

    Article  CAS  PubMed  Google Scholar 

  15. Garcia-Alonso S, Ocana A, Pandiella A (2020) Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond. Trends Cancer 6:130–46. https://doi.org/10.1016/j.trecan.2019.12.010

    Article  CAS  PubMed  Google Scholar 

  16. Yang T, Fu Z, Zhang Y, Wang M, Mao C, Ge W (2020) Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer. Biomed Pharmacother 129:110465. https://doi.org/10.1016/j.biopha.2020.110465

    Article  CAS  PubMed  Google Scholar 

  17. Han Y, Wang J, Liu W, Yuan P, Li Q, Zhang P et al (2019) Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis. Cancer Manag Res 11:4699–706. https://doi.org/10.2147/CMAR.S198962

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istanbul University Istanbul Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey

    Izzet Dogan, Melin Aydan Ahmed, Anıl Yıldız & Sezai Vatansever

Authors
  1. Izzet Dogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melin Aydan Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anıl Yıldız
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sezai Vatansever
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design: ID, MA, AY, and SV.

Acquisition of data: ID, MA, AY, and SV.

Analysis and interpretation of data: ID, MA, AY, and SV.

Drafting of the manuscript: ID, MA, and AY.

Critical revision of the manuscript for important intellectual content: ID, SV.

Corresponding author

Correspondence to Izzet Dogan.

Ethics declarations

Ethical Approval

This study was approved by the Academic Board of Istanbul University Oncology Institute (Number: 229693).

Informed Consent

For this type of research, informed consent is not required.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dogan, I., Ahmed, M.A., Yıldız, A. et al. Rechallenge of Trastuzumab-based Therapy in HER2-Positive Breast Cancer Patients who Progressed Under TDM-1. Indian J Surg Oncol (2024). https://doi.org/10.1007/s13193-024-01935-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13193-024-01935-9

Keywords

Search

Navigation